Oklahoma recalls
3767 federal recalls on file affecting Oklahoma - 392 Oklahoma-specific plus 3375 nationwide. Sourced from CPSC, FDA, USDA, and NHTSA.
- 2026-04-22FDA-DeviceB. BraunClass INationwideB. Braun Hemodialysis Bloodlines, STREAMLINE FRESENIUS FOR DAVITA. Model Number: SL-2000M2095DA.
Potential for the accumulation of small air bubbles in the arterial line due to adherence of blood gases to the tubing under negative pressure.
- 2026-04-22FDA-DeviceB. BraunClass INationwideB. Braun Hemodialysis Bloodlines, STREAMLINE BLOODLINE SET FOR DIALOG. Model Number: SL-2010M2096
Potential for the accumulation of small air bubbles in the arterial line due to adherence of blood gases to the tubing under negative pressure.
- 2026-04-22FDA-DeviceB. BraunClass INationwideStop using B. Braun STREAMLINE BLOODLINE SET
Potential for the accumulation of small air bubbles in the arterial line due to adherence of blood gases to the tubing under negative pressure.
- 2026-04-22FDA-DeviceInsuletClass INationwideStop using affected Omnipod 5 Pods immediately
Due to a manufacturing defect, certain Omnipod 5 Pods from 49 lots have an internal soft cannula tear that results in insulin leaking into the Pod instead of being delivered to the user regardless of basal or bolus delivery. This defect results from damage to the unexposed portion of the soft cannula during manufacturing, which would result in a compromised fluid path. The primary failure mode is pump under-delivery due to loss of insulin to an internal leak; in some cases, the defect may also lead to pump shutoff and cessation of insulin delivery when leaked insulin contacts Pod circuity in a manner that results in an electrical short. Under-delivery of insulin (both basal and bolus insulin) or cessation of insulin put users at risk of hyperglycemia, and complications from acute and chronic hyperglycemia, including dehydration, blurry vision, nausea, vomiting, altered mental status, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), or even death. Users may require hospitalization or medical intervention to treat severe adverse health consequences. Not all devices with the defect will issue an alarm or alert the user. If there is sufficient leakage of insulin to cause a short in the circuity, the Pod will issue a Hazard Alarm that stops all insulin delivery and alerts the user to replace their Pod. In addition, if a user s glucose is trending high and is not responding to insulin delivery, the system may reach the maximum amount of insulin microboluses allowed by the system and trigger the Automated Delivery Restriction (ADR) alert that tells users to check their blood glucose and take appropriate actions (i.e., ADR is a response to persistent hyperglycemia and maximum automated delivery constraints rather than a direct detection of the leak). The magnitude of under-delivery is unknown and based on multiple factors, including how much insulin is being delivered, whether an alarm and/or alert triggers, whether and when the user recognizes the device defect, the duration of Pod use, and the size of the tear.
- 2026-04-22FDA-DrugAvantorClass IIINationwideStop using Avantor Magnesium Chloride
Subpotent drug
- 2026-04-22FDA-DrugCoValence LaboratoriesClass IINationwideStop using Skin Script Blemish Spot Treatment
Failed Stability Specifications
- 2026-04-22FDA-DrugThe Harvard DrugClass IINationwideStop using recalled memantine hydrochloride capsules
Failed Dissolution Specifications
- 2026-04-22FDA-DrugInternational Medication SystemsClass IINationwideStop using recalled epinephrine injection
Lack of Assurance of Sterility
- 2026-04-22FDA-DrugCoValence LaboratoriesClass IIINationwideStop using Island Kinetics Essential Calming Skin Gel
Subpotent Drug
- 2026-04-22FDA-DrugCoValence LaboratoriesClass IIINationwideStop using Island Kinetics Hydrocortisone Balm
Subpotent Drug
- 2026-04-22FDA-DrugCoValence LaboratoriesClass IIINationwideStop using Remedy Gel hydrocortisone
Subpotent Drug
- 2026-04-22FDA-DrugNephronClass IINationwideStop using Nephron SC albuterol solution
Labelling: Illegible label
- 2026-04-22FDA-DrugSun PharmaceuticalClass IINationwideStop using Taro fluocinonide cream
Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.
- 2026-04-22FDA-DrugSun PharmaceuticalClass IINationwideStop using Taro Fluocinonide Cream, Lot AD76251
Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.
- 2026-04-22FDA-DrugSun PharmaceuticalClass IINationwideStop using Taro fluocinonide cream
Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using QC Quality Choice cough drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using QC Quality Choice cough drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using QC Quality Choice cough drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using QC Quality Choice throat drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using QC Quality Choice cough drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using QC Quality Choice cough drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using QC Quality Choice cough drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using MGC Health Menthol Cough Drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using MGC Health cough drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using MGC Health cough drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using Discount Drug Mart cough drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using Discount Drug Mart cough drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using Caring Mill cough drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using Exchange Select cough drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
- 2026-04-22FDA-DrugKang ZhongyuanClass IINationwideStop using Exchange Select cough drops
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
Get notified about new Oklahoma recalls
Free weekly digest. Add Oklahoma to your profile to filter alerts to your state.
Get the Sunday Brief